TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06228157

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine therapy
Description: The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine therapy
Description: The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT06337396

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: WGS and transcriptome analysis
Description: In light of the inconsistencies between the CNV and the phenotypic outcome, we expect that WGS analysis will reveal that part of these CNVs have a more complex structure than the one disentangled by CMA and FISH. We hypothesize that CNV should reflect a perturbed genome folding configuration at several hierarchical levels of chromatin organization, such as disruption of TADs boundaries. To investigate this aspect, we plan to examine expression profiles of immortalized lymphoblastoid B-cell lines (LBLs) derived from normal controls and patients. We expect to find a subset of down- or up-regulated genes located inside the rearranged region which in turn may alter the expression of other genes, possibly leading to perturbation of disease-related pathways
Study: NCT06327594

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound scan
Description: The patients with lung cancer who are scheduled to undergo radical resection of lung cancer are examined by ultrasound at multiple sites of the whole body, including muscle and fat.

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound scan
Description: The patients with lung cancer who are scheduled to undergo radical resection of lung cancer are examined by ultrasound at multiple sites of the whole body, including muscle and fat.

Intervention type: DIAGNOSTIC_TEST
Intervention: CT/MRI scan
Description: The patients with lung cancer who are scheduled to undergo radical resection of lung cancer are examined by abdominal CT/MRI.
Study: NCT04673383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPL026
Description: Intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPL026
Description: Intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SPL026-matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SPL026-matched placebo
Study: NCT05811065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTIVF dosage
Description: Opt-IVF dosage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional drug treament
Description: Traditional drug treatment
Study: NCT06404190

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Diode laser and 3% hydrogen peroxide
Description: Hydrogen peroxide due to its super radicals has a local antimicrobial effect. Since hydrogen peroxide can be easily available in a clinical setting and is cost-effective. It could be used for photo disinfection along with lasers.~The diode lasers that belong to the 655-980 nm spectrum could represent a safer alternative. Because of the transmission or scattering effect on hydroxyapatite, diode lasers have no effect on hard tissues and deposits. The photoactivation procedure uses photolysis of hydrogen peroxide with 810nm laser.~Hydrogen peroxide acts as an endogenous dye, which can increase the laser effect at this level and also generate ROS. Thus the combination of 3% H2O2 and laser light generate hydroxyl radicals as a result of photoactivation.~Therefore, the diode laser stimulation of 3%hydrogen peroxide has been utilized adjunctive to SRP to optimize clinical outcomes.
Study: NCT06327594

Intervention type: DIAGNOSTIC_TEST
Intervention: CT/MRI scan
Description: The patients with lung cancer who are scheduled to undergo radical resection of lung cancer are examined by abdominal CT/MRI.
Study: NCT05391243

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LLETZ
Description: Large loop excision of the transformation zone

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LLETZ
Description: Large loop excision of the transformation zone
Study: NCT04650633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
Study: NCT06278688

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Precision probiotics
Description: The precision probiotics will be designed based on the results of probiotic signatures and consensus clustering described in the PRELIMINARY AND SUPPORTING Data section and available probiotics from GenMont Biotech Inc. (https://www.genmont.com.tw/) The individual gut microbiota will determine the supplement and composition of probiotics.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Precision probiotics
Description: The precision probiotics will be designed based on the results of probiotic signatures and consensus clustering described in the PRELIMINARY AND SUPPORTING Data section and available probiotics from GenMont Biotech Inc. (https://www.genmont.com.tw/) The individual gut microbiota will determine the supplement and composition of probiotics.
Study: NCT04925960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epalrestat
Description: Epalrestat is a noncompetitive and reversible aldose reductase inhibitor (ARI) used for the treatment of diabetic neuropathy in Japan. The drug's ability to safely improve symptoms of neuropathy alone by reducing oxidative stress, increasing glutathione levels, and reducing intracellular sorbitol accumulation make it a desirable medication for PMM2-CDG patients who commonly suffer with various neuropathies. However, work recently conducted by Perlara, a public benefit company with the mandate to screen existing commercially available drugs for possible application in rare diseases, has demonstrated that Epalrestat can also elevate the level PMM2 produced endogenously. This may reduce the severity of the morbidities associated with PMM2-CDG.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsule with be identical in appearance to the Epalrestat capsule. It will contain microcrystalline cellulose filler in a gelatin capsule.
Study: NCT04207476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMF
Description: Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No magnetic field exposure will be given while patients are assigned to this arm for a duration of 1 hour.
Study: NCT04910984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chatbot messages
Description: Automated personalized messages containing HIV testing-related information, motivation and skills

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention-matched educational materials
Description: Attention-matched educational materials manually sent by our research assistant. These educational materials will be retrieved from CDC and WHO websites and curated into short articles (\<200 words) and pictures. All educational materials will be screened by HIV experts from University of Malaya to ensure accuracy before being sent to participants.
Study: NCT06390501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks, 0.1 mg semaglutide once weekly for four weeks, 1.7 mg semaglutide once weekly for four weeks followed by 2.4 mg semaglutide once weekly for eight weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous (s.c. - under the skin) injection
Study: NCT06346730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses to intervention group
Description: experimental and control ,a randomized pretest-posttest study to examine
Study: NCT05937464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exoskeleton ExoAthlet group
Description: This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with exoskeleton ExoAthlet (ExoAtlet 1 model/2019, Russia). Participants were assessed at baseline and post-intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lokomat Free-D group
Description: This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with Lokomat Free-D (Hocoma, Lokomat Pro Free-D model/2015, Switzerland). Participants were assessed at baseline and post-intervention.
Study: NCT05506605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine 100Mg Tab
Description: Switch from Etravirine to Doravirine
Study: NCT04896645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digihaler Albuterol Device by TEVA
Description: Patient with asthma will have their regular albuterol rescue inhaler replaced with Digihaler, they will also be asked to perform gamified spirometry (Aluna) at home
Study: NCT06158529

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spinal cord stimulator
Description: A spinal cord stimulator is an implanted device that sends low levels of electricity directly into the spinal cord to relieve pain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high frequency spinal cord stimulation
Description: A spinal cord stimulator is an implanted device that sends low levels and high frequency of electricity directly into the spinal cord to relieve pain.
Study: NCT06261879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Special sanitary pad
Description: The special sanitary pad is similar to the normal sanitary pad with 0.01 agar gel only. The agar gel is an approved source of food.
Study: NCT04879615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Patients will receive standard dose intravenous alteplase (0.9 mg per kilogram, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)
Study: NCT05885308

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Otago
Description: Group training is compared with training performed at participants' homes, using an online film

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Otago
Description: Group training is compared with training performed at participants' homes, using an online film
Study: NCT05448820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001
Description: Anti-CTLA4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001
Description: Anti-CTLA4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001
Description: Anti-CTLA4 antibody
Study: NCT05989503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril-valsartan
Description: Sacubitril-valsartan titration at the discretion of the treating physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril-valsartan
Description: Sacubitril-valsartan titration at the discretion of the treating physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Either empagliflozin or dapagliflozin 10 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Either empagliflozin or dapagliflozin 10 mg/day
Study: NCT04378426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: PTSD participants in this arm will receive and admixture of up to 50% nitrous oxide and 50% oxygen plus intravenous saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrogen
Description: PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: inhaled gas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: inhaled gas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo infusion
Study: NCT04651634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIT-001 plus CCRT
Description: MIT-001 IV-infusion plus CCRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIT-001 plus CCRT
Description: MIT-001 IV-infusion plus CCRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIT-001 plus CCRT
Description: MIT-001 IV-infusion plus CCRT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MIT-001 plus CCRT
Description: MIT-001 IV-infusion plus CCRT
Study: NCT06002464

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patient will have session of 30 minutes of acupuncture every day during 3 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ESP catheter
Description: Analgesia by Bilateral Continuous erector spine plane block catheter at T9 level for 2 days
Study: NCT04904861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videoconference intervention group
Description: A short face-to-face dyadic group workshop focused on increasing maternal sensitivity was adapted to be carried out virtually by videoconference. The intervention considers 4 sessions, with a weekly frequency, with a minimum of 3 and a maximum of 6 dyads per group led by a monitor (psychologist). The activities are protocolized in a manual and are designed to be carried out by the mother with the baby under one year of age. .
Study: NCT06002464

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral ESP catheter
Description: Analgesia by Bilateral Continuous erector spine plane block catheter at T9 level for 2 days
Study: NCT04947293

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Both groups will practice a physical activity adapted to their motor skills. They will have two group sessions (maximum 5 people per group) in a face-to-face setting, and one independent session at home supported by a video, each week. These programs last 12 weeks, and will be supervised by the same person, a physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Both groups will practice a physical activity adapted to their motor skills. They will have two group sessions (maximum 5 people per group) in a face-to-face setting, and one independent session at home supported by a video, each week. These programs last 12 weeks, and will be supervised by the same person, a physiotherapist.
Study: NCT05350787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART19A
Description: ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
Study: NCT06060366

Intervention type: PROCEDURE
Intervention: Pulmonary endarterectomy
Description: removal of chronic thrombus from pulmonary arterial system
Study: NCT05350787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART19A
Description: ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART19A
Description: ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
Study: NCT04904861

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Psycho-educational intervention : They will receive brochures with information on parenting (once a week for 4 weeks) in addition to the usual care in their primary care center
Study: NCT05653375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based psychoeducation program
Description: In this study, a mindfulness-based psychoeducation program was applied to the experimental group, 2 times a week for 4 weeks, with a total of 8 sessions, including methods such as meditation, body scanning, mindful eating, and breathing work. Measurement tools were applied to the experimental and control groups before and after the program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ongoing life
Description: The control group continued with their lives without any intervention. Only pre-test and post-test were applied. While the program was applied to the experimental group, no intervention was made to the control group.
Study: NCT05872048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: periodontal distractor
Description: custom made device from hyrex screw

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: periodontal distractor
Description: custom made device from hyrex screw
Study: NCT05994170

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduction CTVp1
Description: High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as 5mm margin from GTVp,including pre-induction chemotherapy tumor extension( CTVp1=GTVp+5mm)

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Non-reduction CTVp1
Description: High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as whole nasopharynx as well as 5mm margin from GTVp( CTVp1=GTVp+5mm+whole nasopharynx)
Study: NCT05191043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping Technique
Description: Kinesio taping is a thin, stretchy, elastic cotton strip with an acrylic adhesive that is approximately the same thickness as the epidermis of the skin. When the taping method is followed correctly, the tape effects on the muscle by facilitating a weakened muscle or relaxing an over-used muscle,decreasing pain, fatigue and increasing tissue recovery. Kinesio Taping facilitation technique will be used with fifty percent stretch on rhomboids bilaterally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy
Description: routine physical therapy includes thermotherapy and Transcutaneous electrical nerve stimulation (TENS), the strengthening exercises of lower and middle trapezius, rhomboids and deep neck flexors. Stretching exercises of upper trapezius, pectoralis major and minor. Mobilization of cervicothoracic junction and postural education.~Thermotherapy and transcutaneous electrical nerve stimulation will be used for 10 minutes in each session. Each exercise will be performed in 3 sets of 10 repetitions. Treatment session will have a duration of 30-45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: routine physical therapy includes thermotherapy and Transcutaneous electrical nerve stimulation (TENS), the strengthening exercises of lower and middle trapezius, rhomboids and deep neck flexors. Stretching exercises of upper trapezius, pectoralis major and minor. Mobilization of cervicothoracic junction and postural education.~Thermotherapy and transcutaneous electrical nerve stimulation will be used for 10 minutes in each session. Each exercise will be performed in 3 sets of 10 repetitions. Treatment session will have a duration of 30-45 minutes.
Study: NCT05448820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001
Description: Anti-CTLA4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001
Description: Anti-CTLA4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001
Description: Anti-CTLA4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001
Description: Anti-CTLA4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001
Description: Anti-CTLA4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Anthracycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Anthracycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Anthracycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Anthracycline
Study: NCT05792384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transbronchial lung cryobiopsy with a 1.1 mm flexible cryoprobe
Description: Obtaining lung biopsy samples of patients after lung transplantation through transbronchial lung cryobiopsy with a 1.1 mm flexible cryoprobe

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transbronchial lung biopsy with biopsy forceps
Description: Obtaining lung biopsy samples of patients after lung transplantation through transbronchial lung biopsy with biopsy forceps